Viavi Solutions Inc. Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? Viavi Solutions Inc. Common Stock trades at $37.68 (market cap $10.15B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Viavi Solutions Inc. Common Stock is far larger — about 5.6× Vir Biotechnology Inc. Common Stock's market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, Viavi Solutions Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Viavi Solutions Inc. Common Stock for 6 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| VIAV | VIR | |
|---|---|---|
Market Cap | $10.15B | $1.80B |
Volume | 4,601,222 | 1,782,836 |
Sector | Technology | Health |
52-Week High | $55.33 | $11.78 |
52-Week Low | $13.01 | $5.12 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.20B | $1.36B |
Signals from Pluang's Aura AI — not financial advice
VIAVI Solutions (VIAV) trades at $41.28, down 1.13% on the day, with mixed technical signals showing bearish overall momentum but bullish moving averages. The company demonstrates strong revenue growth with fiscal 2026 revenue reaching $1.52B (up 40% YoY) and has beaten earnings estimates for three consecutive quarters. Recent developments include a U.S. Army contract for defense testing and expanded partnerships in network validation, positioning VIAV for growth in AI data center and defense markets.
While analyst consensus remains strongly bullish with a $60.25 price target (78.95% buy ratings), investors face risks from negative net income margins (-2%) and elevated valuation metrics (P/S 6.24, EV/EBITDA 60.68). The stock's outlook depends on continued execution in high-growth segments and margin improvement to justify current valuations amid competitive pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Viavi Solutions provides network testing, monitoring, and optical technologies. Its products help communications providers, equipment makers, and enterprises build and maintain networks.
Read more on VIAV →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →